Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1059881

Promoter methylation status of ASC/TMS1/PYCARD is associated with decreased overall survival and TNM status in patients with early stage non-small cell lung cancer (NSCLC)


Šutić, Maja; Motzek, Antje; Bubanović, Gordana; Linke, Matthias; Sabol, Ivan; Vugrek, Oliver; Ozretić, Petar; Brčić, Luka; Seiwerth, Sven; Debeljak, Željko et al.
Promoter methylation status of ASC/TMS1/PYCARD is associated with decreased overall survival and TNM status in patients with early stage non-small cell lung cancer (NSCLC) // Translational Lung Cancer Research, 8 (2019), 6; 1000-1015 doi:10.21037/tlcr.2019.12.08 (međunarodna recenzija, članak, znanstveni)


CROSBI ID: 1059881 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Promoter methylation status of ASC/TMS1/PYCARD is associated with decreased overall survival and TNM status in patients with early stage non-small cell lung cancer (NSCLC)

Autori
Šutić, Maja ; Motzek, Antje ; Bubanović, Gordana ; Linke, Matthias ; Sabol, Ivan ; Vugrek, Oliver ; Ozretić, Petar ; Brčić, Luka ; Seiwerth, Sven ; Debeljak, Željko ; Jakovčević, Antonija ; Janevski, Zoran ; Stančić-Rokotov, Dinko ; Vukić-Dugac, Andrea ; Jakopović, Marko ; Samaržija, Miroslav ; Zechner, Ulrich ; Knežević, Jelena

Izvornik
Translational Lung Cancer Research (2218-6751) 8 (2019), 6; 1000-1015

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
ASC/TMS1/PYCARD ; MyD88 ; methylation status ; association ; overall survival ; TNM ; non-small cell lung cancer (NSCLC)

Sažetak
Background: Lung cancer is the leading cause of cancer-related death worldwide, with 5-year overall survival less than 15%. Therefore, it is essential to find biomarkers for early detection and prognosis. Aberrant DNA methylation is a common feature of human cancers and its utility is already recognized in cancer management. The aim of this study was to explore the diagnostic and prognostic value of the promoter methylation status of the ASC/TMS1/PYCARD and MyD88 genes, key adaptor molecules in the activation of the innate immune response and apoptosis pathways. Methods: A total of 50 non-small cell lung cancer (NSCLC) patients were enrolled in the study. Methylation of bisulphite converted DNA was quantified by pyrosequencing in fresh frozen malignant tissues and adjacent non- malignant tissues. Associations between methylation and lung function, tumor grade and overall survival were evaluated using receiver- operating characteristics (ROC) analysis and statistical tests of hypothesis. Results: Methylation level of tested genes is generally low but significantly decreased in tumor tissues (ASC/TMS1/PYCARD, P<0.0001 ; MyD88, P<0.0002), which correlates with increased protein expression. Three CpG sites were identified as promising diagnostic marker candidates ; CpG11 (-63 position) in ASC/TMS1/PYCARD and CpG1 (-253 position) and 2 (-265 position) in MyD88. The association study showed that the methylation status of the ASC/TMS1 CpG4 site (-34 position) in malignant and non-malignant tissues is associated with the overall survival (P=0.019) and the methylation status of CpG8 site (-92 position) is associated with TNM-stage (P=0.011). Conclusions: The methylation status of the ASC/TMS1/PYCARD and MyD88 promoters are promising prognostic biomarker candidates. However, presented results should be considered as a preliminary and should be confirmed on the larger number of the samples.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti



POVEZANOST RADA


Projekti:
HRZZ-IP-2016-06-1441 - Genetički i epigenetički biomarkeri urođene imunosti u KOPB-u i karcinomu pluća (LungInflaCare) (Knežević, Jelena, HRZZ - 2016-06) ( POIROT)

Ustanove:
Institut "Ruđer Bošković", Zagreb,
Medicinski fakultet, Zagreb,
Klinički bolnički centar Osijek,
Klinika za plućne bolesti "Jordanovac"

Citiraj ovu publikaciju

Šutić, Maja; Motzek, Antje; Bubanović, Gordana; Linke, Matthias; Sabol, Ivan; Vugrek, Oliver; Ozretić, Petar; Brčić, Luka; Seiwerth, Sven; Debeljak, Željko et al.
Promoter methylation status of ASC/TMS1/PYCARD is associated with decreased overall survival and TNM status in patients with early stage non-small cell lung cancer (NSCLC) // Translational Lung Cancer Research, 8 (2019), 6; 1000-1015 doi:10.21037/tlcr.2019.12.08 (međunarodna recenzija, članak, znanstveni)
Šutić, M., Motzek, A., Bubanović, G., Linke, M., Sabol, I., Vugrek, O., Ozretić, P., Brčić, L., Seiwerth, S. & Debeljak, Ž. (2019) Promoter methylation status of ASC/TMS1/PYCARD is associated with decreased overall survival and TNM status in patients with early stage non-small cell lung cancer (NSCLC). Translational Lung Cancer Research, 8 (6), 1000-1015 doi:10.21037/tlcr.2019.12.08.
@article{article, year = {2019}, pages = {1000-1015}, DOI = {10.21037/tlcr.2019.12.08}, keywords = {ASC/TMS1/PYCARD, MyD88, methylation status, association, overall survival, TNM, non-small cell lung cancer (NSCLC)}, journal = {Translational Lung Cancer Research}, doi = {10.21037/tlcr.2019.12.08}, volume = {8}, number = {6}, issn = {2218-6751}, title = {Promoter methylation status of ASC/TMS1/PYCARD is associated with decreased overall survival and TNM status in patients with early stage non-small cell lung cancer (NSCLC)}, keyword = {ASC/TMS1/PYCARD, MyD88, methylation status, association, overall survival, TNM, non-small cell lung cancer (NSCLC)} }
@article{article, year = {2019}, pages = {1000-1015}, DOI = {10.21037/tlcr.2019.12.08}, keywords = {ASC/TMS1/PYCARD, MyD88, methylation status, association, overall survival, TNM, non-small cell lung cancer (NSCLC)}, journal = {Translational Lung Cancer Research}, doi = {10.21037/tlcr.2019.12.08}, volume = {8}, number = {6}, issn = {2218-6751}, title = {Promoter methylation status of ASC/TMS1/PYCARD is associated with decreased overall survival and TNM status in patients with early stage non-small cell lung cancer (NSCLC)}, keyword = {ASC/TMS1/PYCARD, MyD88, methylation status, association, overall survival, TNM, non-small cell lung cancer (NSCLC)} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
    • Emerging Sources Citation Index (ESCI)
  • Scopus


Citati





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font